{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:27:10Z","timestamp":1785331630112,"version":"3.55.0"},"reference-count":54,"publisher":"American Society of Hematology","issue":"13","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/legalcode"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Understanding the biological and clinical impact of copy number aberrations (CNAs) on the development of precision therapies in cancer remains an unmet challenge. Genetic amplification of chromosome 1q (chr1q-amp) is a major CNA conferring an adverse prognosis in several types of cancer, including in the blood cancer multiple myeloma (MM). Although several genes across chromosome 1 (chr1q) portend high-risk MM disease, the underpinning molecular etiology remains elusive. Here, with reference to the 3-dimensional (3D) chromatin structure, we integrate multi-omics data sets from patients with MM with genetic variables to obtain an associated clinical risk map across chr1q and to identify 103 adverse prognosis genes in chr1q-amp MM. Prominent among these genes, the transcription factor PBX1 is ectopically expressed by genetic amplification and epigenetic activation of its own preserved 3D regulatory domain. By binding to reprogrammed superenhancers, PBX1 directly regulates critical oncogenic pathways and a FOXM1-dependent transcriptional program. Together, PBX1 and FOXM1 activate a proliferative gene signature that predicts adverse prognosis across multiple types of cancer. Notably, pharmacological disruption of the PBX1-FOXM1 axis with existing agents (thiostrepton) and a novel PBX1 small molecule inhibitor (T417) is selectively toxic against chr1q-amp myeloma and solid tumor cells. Overall, our systems medicine approach successfully identifies CNA-driven oncogenic circuitries, links them to clinical phenotypes, and proposes novel CNA-targeted therapy strategies in MM and other types of cancer.<\/jats:p>","DOI":"10.1182\/blood.2021014391","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T15:54:42Z","timestamp":1641916482000},"page":"1939-1953","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":34,"title":["Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9795-3059","authenticated-orcid":false,"given":"Nikolaos","family":"Trasanidis","sequence":"first","affiliation":[{"name":"Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Katsarou","sequence":"additional","affiliation":[{"name":"Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom;"},{"name":"Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanagaraju","family":"Ponnusamy","sequence":"additional","affiliation":[{"name":"Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4393-2794","authenticated-orcid":false,"given":"Yao-An","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Pathology,"},{"name":"Department of Oncology,"},{"name":"Department of Gynecology and Obstetrics, and"},{"name":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD;"},{"name":"Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1152-6959","authenticated-orcid":false,"given":"Ioannis V.","family":"Kostopoulos","sequence":"additional","affiliation":[{"name":"Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom;"},{"name":"Department of Biology, School of Science, National and Kapodistrian University of Athens, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bien","family":"Bergonia","sequence":"additional","affiliation":[{"name":"Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Keren","sequence":"additional","affiliation":[{"name":"Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paudel","family":"Reema","sequence":"additional","affiliation":[{"name":"Imperial Experimental Cancer Medicine Centre and Cancer Research UK Imperial Centre, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Xiao","sequence":"additional","affiliation":[{"name":"Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1102-8298","authenticated-orcid":false,"given":"Richard M.","family":"Szydlo","sequence":"additional","affiliation":[{"name":"Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierangela M. R.","family":"Sabbattini","sequence":"additional","affiliation":[{"name":"Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene A. G.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford, United Kingdom;"},{"name":"Oxford Biomedical Research Centre Blood Theme, National Institute for Health Research Oxford Biomedical Centre, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger W.","family":"Auner","sequence":"additional","affiliation":[{"name":"Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom;"},{"name":"Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3807-3638","authenticated-orcid":false,"given":"Kikkeri N.","family":"Naresh","sequence":"additional","affiliation":[{"name":"Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London, United Kingdom;"},{"name":"Imperial Experimental Cancer Medicine Centre and Cancer Research UK Imperial Centre, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1453-8576","authenticated-orcid":false,"given":"Aristeidis","family":"Chaidos","sequence":"additional","affiliation":[{"name":"Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom;"},{"name":"Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology,"},{"name":"Department of Oncology,"},{"name":"Department of Gynecology and Obstetrics, and"},{"name":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7534-0785","authenticated-orcid":false,"given":"Luca","family":"Magnani","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4011-5238","authenticated-orcid":false,"given":"Valentina S.","family":"Caputo","sequence":"additional","affiliation":[{"name":"Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom;"},{"name":"Cancer Biology and Therapy Laboratory, School of Applied Science, London South Bank University, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9566-9780","authenticated-orcid":false,"given":"Anastasios","family":"Karadimitris","sequence":"additional","affiliation":[{"name":"Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom;"},{"name":"Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7832","key":"2022050218130396500_B1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41586-020-2698-6","article-title":"Pervasive chromosomal instability and karyotype order in tumour evolution","volume":"587","author":"Watkins","year":"2020","journal-title":"Nature."},{"issue":"7781","key":"2022050218130396500_B2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","article-title":"Pan-cancer whole-genome analyses of metastatic solid tumours","volume":"575","author":"Priestley","year":"2019","journal-title":"Nature."},{"issue":"7283","key":"2022050218130396500_B3","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature."},{"issue":"9","key":"2022050218130396500_B4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrc.2017.63","article-title":"Evolutionary biology of high-risk multiple myeloma","volume":"17","author":"Pawlyn","year":"2017","journal-title":"Nat Rev Cancer."},{"issue":"27","key":"2022050218130396500_B5","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1200\/JCO.2008.20.6136","article-title":"Prognostic significance of copy-number alterations in multiple myeloma","volume":"27","author":"Avet-Loiseau","year":"2009","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022050218130396500_B6","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1080\/10428194.2016.1260126","article-title":"Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation","volume":"58","author":"Shah","year":"2017","journal-title":"Leuk Lymphoma."},{"issue":"7","key":"2022050218130396500_B7","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1038\/s41375-020-01096-y","article-title":"Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial","volume":"35","author":"Croft","year":"2021","journal-title":"Leukemia."},{"issue":"15","key":"2022050218130396500_B8","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","article-title":"A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood."},{"issue":"12","key":"2022050218130396500_B9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J."},{"issue":"1","key":"2022050218130396500_B10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia."},{"issue":"16","key":"2022050218130396500_B11","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2011.36.5726","article-title":"Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival","volume":"30","author":"Avet-Loiseau","year":"2012","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022050218130396500_B12","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood."},{"key":"2022050218130396500_B13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10245330512331390140","article-title":"Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma","volume":"10","author":"Shaughnessy","year":"2005","journal-title":"Hematology."},{"issue":"1","key":"2022050218130396500_B14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18632\/oncotarget.105","article-title":"Over-expression of CKS1B activates both MEK\/ERK and JAK\/STAT3 signaling pathways and promotes myeloma cell drug-resistance","volume":"1","author":"Shi","year":"2010","journal-title":"Oncotarget."},{"issue":"1","key":"2022050218130396500_B15","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ccell.2017.05.011","article-title":"ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma","volume":"32","author":"Marchesini","year":"2017","journal-title":"Cancer Cell."},{"issue":"5","key":"2022050218130396500_B16","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.3324\/haematol.2019.221176","article-title":"IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification","volume":"105","author":"Teoh","year":"2020","journal-title":"Haematologica."},{"issue":"6","key":"2022050218130396500_B17","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood."},{"issue":"19","key":"2022050218130396500_B18","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1158\/0008-5472.CAN-09-0773","article-title":"BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells","volume":"69","author":"Mani","year":"2009","journal-title":"Cancer Res."},{"issue":"6","key":"2022050218130396500_B19","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood.V99.6.1885","article-title":"Myeloid cell factor-1 is a critical survival factor for multiple myeloma","volume":"99","author":"Zhang","year":"2002","journal-title":"Blood."},{"issue":"5","key":"2022050218130396500_B20","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1182\/blood.V90.5.1982","article-title":"MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells","volume":"90","author":"Teoh","year":"1997","journal-title":"Blood."},{"issue":"33","key":"2022050218130396500_B21","doi-asserted-by":"crossref","first-page":"34276","DOI":"10.18632\/oncotarget.5371","article-title":"Detection of recurrent cytogenetic aberrations in multiple myeloma: a comparison between MLPA and iFISH","volume":"6","author":"Zang","year":"2015","journal-title":"Oncotarget."},{"issue":"5","key":"2022050218130396500_B22","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.7150\/jca.37313","article-title":"Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma","volume":"11","author":"Fu","year":"2020","journal-title":"J Cancer."},{"issue":"11","key":"2022050218130396500_B23","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood-2008-06-161281","article-title":"Regulation of multiple myeloma survival and progression by CD1d","volume":"113","author":"Spanoudakis","year":"2009","journal-title":"Blood."},{"issue":"4","key":"2022050218130396500_B24","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3324\/haematol.2011.046821","article-title":"Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma","volume":"97","author":"Kassambara","year":"2012","journal-title":"Haematologica."},{"issue":"1","key":"2022050218130396500_B25","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1038\/s41467-021-25704-2","article-title":"Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma","volume":"12","author":"Alvarez-Benayas","year":"2021","journal-title":"Nat Commun."},{"issue":"610","key":"2022050218130396500_B26","doi-asserted-by":"crossref","first-page":"eabf0113","DOI":"10.1126\/scitranslmed.abf0113","article-title":"Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemia","volume":"13","author":"Iskander","year":"2021","journal-title":"Sci Transl Med."},{"key":"2022050218130396500_B27","article-title":"The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma","author":"Ponnusamy","journal-title":"Haematologica."},{"issue":"1","key":"2022050218130396500_B28","doi-asserted-by":"crossref","first-page":"101989","DOI":"10.1016\/j.isci.2020.101989","article-title":"Brd2\/4 and Myc regulate alternative cell lineage programmes during early osteoclast differentiation in\u00a0vitro","volume":"24","author":"Caputo","year":"2020","journal-title":"iScience."},{"issue":"21","key":"2022050218130396500_B29","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1182\/blood.V122.21.532.532","article-title":"Interim analysis of the MMRF CoMMpass trial, a longitudinal study in multiple myeloma relating clinical outcomes to genomic and immunophenotypic profiles","volume":"122","author":"Keats","year":"2013","journal-title":"Blood."},{"issue":"1","key":"2022050218130396500_B30","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1038\/s41467-017-01793-w","article-title":"3D genome of multiple myeloma reveals spatial genome disorganization associated with copy number variations","volume":"8","author":"Wu","year":"2017","journal-title":"Nat Commun."},{"issue":"7","key":"2022050218130396500_B31","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.cell.2014.11.021","article-title":"A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping","volume":"159","author":"Rao","year":"2014","journal-title":"Cell."},{"issue":"4","key":"2022050218130396500_B32","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2141.2009.07869.x","article-title":"Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 amplicon","volume":"147","author":"Sawyer","year":"2009","journal-title":"Br J Haematol."},{"issue":"6","key":"2022050218130396500_B33","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood."},{"issue":"19","key":"2022050218130396500_B34","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood-2017-09-808063","article-title":"Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma","volume":"131","author":"Jin","year":"2018","journal-title":"Blood."},{"issue":"11","key":"2022050218130396500_B35","doi-asserted-by":"crossref","first-page":"e1002368","DOI":"10.1371\/journal.pgen.1002368","article-title":"PBX1 genomic pioneer function drives ER\u03b1 signaling underlying progression in breast cancer","volume":"7","author":"Magnani","year":"2011","journal-title":"PLoS Genet."},{"issue":"26","key":"2022050218130396500_B36","doi-asserted-by":"crossref","first-page":"21878","DOI":"10.18632\/oncotarget.4243","article-title":"The pioneer factor PBX1 is a novel driver of metastatic progression in ER\u03b1-positive breast cancer","volume":"6","author":"Magnani","year":"2015","journal-title":"Oncotarget."},{"issue":"11","key":"2022050218130396500_B37","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1002\/ijc.30680","article-title":"Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer","volume":"140","author":"Wang","year":"2017","journal-title":"Int J Cancer."},{"issue":"10","key":"2022050218130396500_B38","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1038\/s41375-020-0785-1","article-title":"Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis","volume":"34","author":"Sarin","year":"2020","journal-title":"Leukemia."},{"key":"2022050218130396500_B39","first-page":"2020.02","article-title":"sciCNV: High-throughput paired profiling of transcriptomes and DNA copy number variations at single cell resolution","author":"Mahdipour-Shirayeh","year":"2020","journal-title":"bioRxiv."},{"issue":"1","key":"2022050218130396500_B40","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1186\/s12885-018-5015-0","article-title":"Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma","volume":"18","author":"Gu","year":"2018","journal-title":"BMC Cancer."},{"issue":"1","key":"2022050218130396500_B41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ccr.2012.12.001","article-title":"NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers","volume":"23","author":"Zhou","year":"2013","journal-title":"Cancer Cell."},{"issue":"9","key":"2022050218130396500_B42","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nchem.1114","article-title":"The transcription factor FOXM1 is a cellular target of the natural product thiostrepton","volume":"3","author":"Hegde","year":"2011","journal-title":"Nat Chem."},{"issue":"1","key":"2022050218130396500_B43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2010.030296","article-title":"Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma","volume":"96","author":"Hose","year":"2011","journal-title":"Haematologica."},{"issue":"1","key":"2022050218130396500_B44","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood."},{"issue":"11","key":"2022050218130396500_B45","doi-asserted-by":"crossref","first-page":"103297","DOI":"10.1016\/j.isci.2021.103297","article-title":"Development of small molecule inhibitors targeting PBX1 transcription signaling as a novel cancer therapeutic strategy","volume":"24","author":"Shen","year":"2021","journal-title":"iScience"},{"issue":"7793","key":"2022050218130396500_B46","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1913-9","article-title":"Patterns of somatic structural variation in human cancer genomes","volume":"578","author":"Li","year":"2020","journal-title":"Nature."},{"issue":"1","key":"2022050218130396500_B47","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/gcc.20109","article-title":"Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q","volume":"42","author":"Sawyer","year":"2005","journal-title":"Genes Chromosomes Cancer."},{"issue":"10","key":"2022050218130396500_B48","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1101\/gad.259796.115","article-title":"Hypoxia drives transient site-specific copy gain and drug-resistant gene expression","volume":"29","author":"Black","year":"2015","journal-title":"Genes Dev."},{"key":"2022050218130396500_B49","article-title":"Chromothripsis as a pathogenic driver of multiple myeloma","author":"Maura","year":"2021","journal-title":"Semin Cell Dev Biol."},{"issue":"1","key":"2022050218130396500_B50","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1038\/s41467-021-25469-8","article-title":"Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma","volume":"12","author":"Maclachlan","year":"2021","journal-title":"Nat Commun."},{"issue":"2","key":"2022050218130396500_B51","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3390\/cancers13020256","article-title":"Gain\/amplification of chromosome arm 1q21 in multiple myeloma","volume":"13","author":"Hanamura","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"12","key":"2022050218130396500_B52","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1074\/jbc.RA118.006057","article-title":"Inhibition of the deubiquitinase USP9x induces pre-B cell homeobox 1 (PBX1) degradation and thereby stimulates prostate cancer cell apoptosis","volume":"294","author":"Liu","year":"2019","journal-title":"J Biol Chem."},{"issue":"3","key":"2022050218130396500_B53","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.18632\/oncotarget.6151","article-title":"Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients","volume":"7","author":"Calura","year":"2016","journal-title":"Oncotarget."},{"issue":"6","key":"2022050218130396500_B54","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cell.2019.10.039","article-title":"Functional enhancers shape extrachromosomal oncogene amplifications","volume":"179","author":"Morton","year":"2019","journal-title":"Cell."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/13\/1939\/1889501\/bloodbld2021014391.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/13\/1939\/1889501\/bloodbld2021014391.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T14:14:13Z","timestamp":1651500853000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/13\/1939\/483430\/Systems-medicine-dissection-of-chr1q-amp-reveals-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":54,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,3,31]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021014391","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.11.17.469031","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]}}}